Relacorilant clinical trials
Also written CORT125134.
How each study uses relacorilant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the relacorilant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 25 Mar 2026 · LIFYORLI (COPACKAGED) · NDA 220641 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
26 studies that test it; most in 2018 (7)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 4 |
| 2017 | 1 |
| 2018 | 7 |
| 2019 | 1 |
| 2020 | 5 |
| 2021 | 1 |
| 2022 | 2 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 22 · Other 4
Corcept Therapeutics (22) · University of Chicago (2) · The University of Texas Health Science Center at San Antonio (1) · ARCAGY/ GINECO GROUP (1)
Often tested with
Tested in the same studies.
Albumin-Bound Paclitaxel (4) · Paclitaxel (4) · Itraconazole (1) · Prednisone (1) · Glucose (1) · Midazolam (1) · Metoprolol (1) · Pioglitazone (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test relacorilant.
- Dec 2026Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing SyndromePhase 2 · Corcept Therapeutics
- Sep 2027Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic AdenocarcinomaPhase 2 · Corcept Therapeutics
- Oct 2027A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate CancerPhase 2 · University of Chicago
Studies
Open first, then newest update. How each study uses relacorilant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 26
- Relacorilant in Patients With Poorly Controlled Type 2 Diabetes and Autonomous Cortisol SecretionNot yet recruitingPhase 1/2The University of Texas Health Science Center at San AntonioNCT07925801Written as Relacorilant
- Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingPhase 2Corcept TherapeuticsNCT07259317Written as Relacorilant
- A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate CancerRecruitingPhase 2University of ChicagoNCT05726292Written as Relacorilant
- Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical CancerNot yet recruitingPhase 2ARCAGY/ GINECO GROUPNCT07763496Written as Relacorilant
- Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing SyndromeActive, not recruitingPhase 2Corcept TherapeuticsNCT03604198Written as relacorilant
- Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube CancerActive, not recruitingPhase 3Corcept TherapeuticsNCT05257408Written as Relacorilant 150 mg
- Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate CancerCompletedPhase 1University of ChicagoNCT03674814Written as Relacorilant
- Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedPhase 2Corcept TherapeuticsNCT03776812Written as Relacorilant
- A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal AdenomasCompletedPhase 3Corcept TherapeuticsNCT04308590Written as Relacorilant
- A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing SyndromeCompletedPhase 3Corcept TherapeuticsNCT03697109Written as Relacorilant
- Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)CompletedPhase 1Corcept TherapeuticsNCT04373265Written as Relacorilant
- Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal AdenocarcinomaTerminatedPhase 3Corcept TherapeuticsNCT04329949Written as Relacorilant, 100 mg and 25 mg
- A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of RelacorilantCompletedPhase 1Corcept TherapeuticsNCT06094725Written as Relacorilant
- A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male SubjectsCompletedPhase 1Corcept TherapeuticsNCT06094712Written as CORT125134
- A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy SubjectsCompletedPhase 1Corcept TherapeuticsNCT06094738Written as Relacorilant under fasted conditions
- A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy SubjectsCompletedPhase 1Corcept TherapeuticsNCT06094790Written as CORT125134 150 mg
- Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy ParticipantsCompletedPhase 1Corcept TherapeuticsNCT05347979Written as Relacorilant
- Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid TumorsCompletedPhase 1/2Corcept TherapeuticsNCT02762981Written as Relacorilant with nab-paclitaxel
- T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy VolunteersCompletedPhase 1Corcept TherapeuticsNCT04795479Written as Relacorilant
- Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its MetabolitesCompletedPhase 1Corcept TherapeuticsNCT03512548Written as Relacorilant 350mg
See all 26 studies that test relacorilant →
Given beside what is tested · 1 — relacorilant is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
Codes
What other systems call relacorilant · ClinicalTrials.gg INT001143
- MeSH (NLM) C000633444relacorilantOne source NLM
- UNII (FDA) 2158753C7ERELACORILANTConfirmed FDA, NLM, Wikidata
- Wikidata Q48845466relacorilantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C127838RelacorilantOne source FDA
- DrugBank DB14976One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000633444 | relacorilant | One source NLM |
| UNII (FDA) | 2158753C7E | RELACORILANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q48845466 | relacorilant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C127838 | Relacorilant | One source FDA |
| DrugBank | DB14976 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.